InvestorsHub Logo
Followers 41
Posts 1956
Boards Moderated 0
Alias Born 03/24/2014

Re: exwannabe post# 435552

Sunday, 01/16/2022 1:59:28 PM

Sunday, January 16, 2022 1:59:28 PM

Post# of 701119
Wrong again!!

I guess you know better than
https://brainstrust.org.uk/wp-content/uploads/2019/03/brainstrust-know-hows-immunotherapy-10.02.19-1.pdf
DCVax®-L can be accessed privately on a very limited compassionate-use basis under the Specials regulation in the UK


While we're at it...what did you say the capacity for Sawston was? I recall 4-6 patients per month, correct?

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html
The Company anticipates that Phase 1A alone will be able to manufacture DCVax-L products for 45-50 patients per month, or 450-500 patients per year
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News